|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.12 EUR | -0.42% |
|
+0.29% | -8.33% |
| 07-10 | Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector | CI |
| 07-10 | Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma | MT |
| Market Cap | 91.49B 105B 84.39B 77.94B 148B 9,976B 150B 1,008B 396B 4,915B 393B 384B 16,895B | P/E 2026 * |
11.5x | P/E 2027 * | 10.6x |
|---|---|---|---|---|---|
| Enterprise Value | 101B 116B 93.27B 86.15B 163B 11,026B 166B 1,114B 438B 5,432B 434B 425B 18,674B | EV / Sales 2026 * |
2.15x | EV / Sales 2027 * | 1.94x |
| Free-Float |
89% | Yield 2026 * |
5.58% | Yield 2027 * | 5.91% |
Last Transcript: Sanofi
| 1 day | -0.42% | ||
| 1 week | +0.29% | ||
| Current month | +1.36% | ||
| 1 month | -0.47% | ||
| 3 months | -5.06% | ||
| 6 months | -9.83% | ||
| Current year | -8.33% |
| 1 week | 74.43 |  | 77.11 |
| 1 month | 71.25 | | 77.11 |
| Current year | 71.25 | | 84.99 |
| 1 year | 71.25 | | 90.75 |
| 3 years | 71.25 | | 110.82 |
| 5 years | 71.25 | | 110.82 |
| 10 years | 62.88 | | 110.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 57 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.42% | +0.29% | - | - | 105B | |
| -2.33% | -2.09% | +49.88% | +170.51% | 1,060B | |
| -0.82% | -2.30% | +63.79% | +62.00% | 619B | |
| -0.73% | -4.98% | +28.91% | +82.99% | 438B | |
| +0.33% | -1.17% | +31.07% | +27.09% | 333B | |
| -0.02% | -2.85% | +29.15% | +45.24% | 282B | |
| -3.89% | -11.22% | +22.81% | +27.30% | 267B | |
| +0.66% | -1.42% | -26.59% | -37.71% | 218B | |
| -0.06% | -2.88% | +23.07% | +62.33% | 196B | |
| -3.72% | -1.10% | +18.41% | +70.56% | 161B | |
| Average | -1.10% | -3.25% | +26.72% | +56.70% | 397.1B | |
| Weighted average by Cap. | -1.29% | -2.96% | +36.75% | +83.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 46.95B 53.68B 43.31B 40B 75.9B 5,119B 77.17B 517B 203B 2,522B 202B 197B 8,670B | 50.04B 57.2B 46.15B 42.63B 80.88B 5,456B 82.24B 551B 217B 2,688B 215B 210B 9,240B |
| Net income | 7.99B 9.14B 7.37B 6.81B 12.92B 871B 13.13B 88.06B 34.58B 429B 34.3B 33.55B 1,476B | 8.9B 10.18B 8.21B 7.58B 14.39B 971B 14.63B 98.12B 38.53B 478B 38.22B 37.38B 1,644B |
| Net Debt | 9.63B 11.01B 8.88B 8.21B 15.57B 1,050B 15.83B 106B 41.68B 517B 41.34B 40.44B 1,779B | 5.52B 6.31B 5.09B 4.7B 8.92B 602B 9.07B 60.83B 23.89B 296B 23.69B 23.18B 1,019B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-10 | €76.12 | -0.42% | 8,773 |
| 26-07-09 | €76.44 | +1.39% | 19,591 |
| 26-07-08 | €75.39 | -0.57% | 11,143 |
| 26-07-07 | €75.82 | +1.51% | 13,933 |
| 26-07-06 | €74.69 | -1.59% | 29,548 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- SNW Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
